EyeBio
United Kingdom · $130.0M raised
- Business Model
- B2B
- Website
- merck.com
- Total Funding
- $130.0M
- Last Round
- $65.0M Series ANov 2023
- Rounds
- 2
About
Ophthalmology biotechnology company developing next-generation therapies to protect, restore, and improve vision; acquired by Merck.
Summary
EyeBio is a Biotech company based in United Kingdom. It has raised $130.0M in total across 2 rounds, most recently a $65.0M Series A round in Nov 2023. Investors include Bain Capital Life Sciences, Omega Funds and SV Health Investors.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Nov 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...